Table 1 Baseline Patient Characteristics of the Patent group and the Occluded group at graft-level
Patent (910) | Occluded (45) | P | |
|---|---|---|---|
Age | 64 (57–69) | 65 (58–69) | 0.819 |
Female (n, %) | 250 (27.5) | 22 (48.9) | 0.003 |
BMI | 25.3 (23.1–27.4) | 25.0 (23.1–27.7) | 0.924 |
Hypertension (n, %) | 601 (66.0) | 30 (66.7) | 1.000 |
Diabetes (n, %) | 359 (39.5) | 20 (44.4) | 0.536 |
Insulin treatment | 104 (11.4) | 9 (20) | 0.095 |
Hyperlipidemia (n, %) | 459 (50.4) | 25 (55.6) | 0.544 |
Previous stroke (n, %) | 147 (16.15) | 4 (8.89) | 0.217 |
Smoking (n, %) | 245 (26.92) | 12 (26.67) | 1.000 |
PVD (n, %) | 128 (14.07) | 9 (20.00) | 0.275 |
Ventricular aneurysm (n, %) | 28 (3.08) | 2 (4.44) | 0.648 |
Previous MI (n, %) | 159 (17.47) | 7 (15.56) | 0.843 |
PCI | 136 (14.95) | 6 (13.33) | 0.835 |
Arrhythmia (n, %) | 20 (2.20) | 0 (0.00) | 0.619 |
AMI (n, %) | 243 (15.71) | 12 (26.67) | 1.000 |
Diseased vessels | 3.0 (3.0–3.0) | 3.0 (3.0–3.0) | 0.251 |
Left main disease (n, %) | 202 (22.20) | 7 (15.56) | 0.358 |
NYHA (n, %) | 0.399 | ||
I | 3 (0.33) | 0 (0.00) | |
II | 699 (76.81) | 36 (80.00) | |
III | 201 (22.09) | 8 (17.78) | |
IV | 7 (0.77) | 1 (2.22) | |
LVEF (%, ± s) | 63.6 (55.6–68.7) | 65.3 (58.2–69.8) | 0.354 |
LVEF < 40% (n, %) | 29 (3.19) | 2 (4.44) | 0.654 |
EuroSCORE II | 1.0 (0.7–1.5) | 1.1 (0.7–1.4) | 0.744 |
Triglycerides | 1.5 (1.1–2.1) | 1.6 (1.4–2.5) | 0.024 |
PLT | 199.0 (166.0–245.0) | 185.0 (154.0–229.5) | 0.111 |
Preoperative creatinine (μmol/ml, ± s) | 73.0 (62.0–87.0) | 69.0 (58.0–79.5) | 0.059 |